Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roblox Corp (RBLX) vs Revvity Inc (RVTY) Price & Performance

Roblox CorpTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Roblox Corp vs Revvity Inc — how do they compare? Roblox Corp trades at $48.09 (market cap $32.52B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Roblox Corp is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Revvity Inc for 12 Days on average.

RBLXRVTY
Market Cap
$32.52B$16.98B
Volume
14,552,0451,456,900
Sector
TechnologyHealth
52-Week High
$138.56$157.36
52-Week Low
$35.54$82.26
Typical Hold Time
93 Days12 Days
Enterprise Value
$31.34B$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roblox Corp

RBLX trades at $48.09, up 3.62% today, showing strong momentum despite a bearish technical signal. The stock has beaten earnings expectations for three consecutive quarters, with revenue growing from $2.2B in 2022 to $4.9B in 2025. However, the company remains unprofitable with a net income margin of -17.61% and negative ROE of -396.28%. Recent news highlights mixed sentiment, including a Jefferies downgrade to Underperform on September 28, 2026, citing concerns about bookings growth, offset by optimism around AI tools unveiled at the developer conference.

The outlook for RBLX hinges on balancing robust revenue growth against persistent losses. The consensus price target of $50.85 suggests modest upside, but high P/B of 213.94 and negative profitability metrics pose risks. Key opportunities include AI-driven creator tools and expanding user engagement, while threats involve booking deceleration and competitive pressure. Investors should weigh the company's growth trajectory against its path to profitability.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RBLX
50% Buy50% Sell
Avg holding period · 93 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Roblox Corp

Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.

Read more on RBLX →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →